Openbookopenbook
Equity
Hikma Pharmaceuticals PLC(HIK)
GBX --+0.00%
Reward57Moderate
Risk36Moderate
📊75%Data
6.7% dividend yield
HIK
+0.0 · +0.00%
GBX · LSE
Hikma Pharmaceuticals PLC | Healthcare
Dividend King
Market Cap:2.76Bn
ℹ️
Reward Rating
57
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
36
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on HIK to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 2096p.

What is Hikma Pharmaceuticals PLC?

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.

HIK · Verdict

Solid reward · moderate risk

HIK scores well on valuation and cash flow with no major weaknesses flagged in the model.

Based on 88% data coverage

HIK · Verdict

What’s working & what to watch

Strengths 3

  • Valuation72/100

    P/E 7.5× · PEG 2.38

  • Cash flow67/100

    5% free-cash-flow margin

  • Volatility65/100

    Above average

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Hikma Pharmaceuticals PLC?

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 2.76B, and a P/E ratio of 9.2x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (57)

The scoring profile indicates moderate reward potential, with valuation and profitability as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap2.76B
P/E Ratio9.237
Dividend Yield6.73%
52 Week High2132.0025
52 Week Low1233
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding221M
No. of Employees9,400
IndustryDrug Manufacturers - Specialty & Generic
ExchangeLSE
Beta0.653
CurrencyGBX
Websitewww.hikma.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.